항정신병약 시장 규모는 2023년에 134억 476만 달러에 달했습니다. 이 시장은 2024-2030년의 예측 기간 중 6.62%의 CAGR로 확대하며, 2030년에는 196억 5,329만 달러에 달할 전망입니다. 항정신병약 시장은 정신분열증, 정신분열성 정서장애, 양극성 장애, 중증 우울증, 성격장애의 정신병적 증상과 같은 정신장애의 유병률 증가로 인해 상당한 시장 성장세를 보이고 있습니다. 정신질환에 취약한 노령 인구 증가, 정신건강에 대한 정부 및 의료기관의 관심 증가 등이 항정신병약물 수요 급증에 기여할 것으로 보입니다. 또한 시장내 약물 승인 및 출시가 급증하면서 연구개발 활동이 활발해짐에 따라 항정신병 약품에 대한 수요가 증가하고 있으며, 2024-2030년의 예측 기간 중 상당한 CAGR로 성장할 것으로 예상됩니다.
세계보건기구(WHO)는 2022년 우울증은 전 세계에서 흔한 질병으로 인구의 3.8%가 앓고 있는 것으로 추정되며, 그 중 성인의 5.0%, 60세 이상 노인의 5.7%가 앓고 있는 것으로 추정된다고 밝혔습니다. 또한 4,000만 명에 가까운 사람들이 양극성 장애를 경험하고 있으며, 4,000만 명(아동 및 청소년 포함)이 비사회적 장애를 앓고 있다고 밝혔습니다.
위의 통계에서 정신장애의 유병률은 전 세계에서 높으며, 결국 위의 장애 치료에 종사하는 항정신병약에 대한 수요를 증가시키고 있다는 결론을 내릴 수 있습니다.
세계의 항정신병약 시장에 대해 조사했으며, 시장의 개요와 적응증별, 약제 클래스별, 유통 채널별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.
Antipsychotic Drugs Market by Indication (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, and Others), Drug Class (First Generation or Typical Antipsychotics [Haloperidol, Prochlorperazine, and Others], Second Generation or Atypical Antipsychotics [Clozapine, Risperidone, and Others], Third Generation [Abilify and Others], Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing burden of mental disorders such as schizophrenia, dementia & others, and the increasing research & developmental activities in antipsychotic drugs across the globe
The antipsychotic drugs market was valued at USD 13,404.76 million in 2023 and is likely to register a CAGR of 6.62% during the forecast period from 2024 to 2030 to reach USD 19,653.29 million by 2030. The antipsychotic drugs market is observing substantial market growth due to the growing prevalence of mental disorders such as schizophrenia, schizoaffective disorder, bipolar disorder, severe depression, psychotic symptoms of a personality disorder, and others. The increasing geriatric population base prone to mental disorders, the increasing focus of governments and healthcare organizations on mental health, and others will aid in surging the demand for antipsychotic drugs. Moreover, the rising research & developmental activities along with the surging drug approvals and launches in the market will create a requisite for antipsychotic drugs owing to which the market is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.
Antipsychotic Drugs Market Dynamics:
The World Health Organization (WHO) in 2022, stated that depression is a common illness worldwide, with an estimated 3.8% of the population affected, including 5.0% among adults and 5.7% among adults older than 60 years. Also, it stated that nearly 40 million people experienced bipolar disorder and 40 million people, including children and adolescents were living with conduct-dissocial disorder.
From the above statistics, it can be concluded that the prevalence of mental disorders is high across the globe, ultimately increasing the demand for antipsychotic drugs, engaged in the treatment of the above-mentioned disorders.
Furthermore, the latest approvals in the antipsychotic drugs market will push forward its revenue shares in the market. For example, In April 2023, Otsuka America Pharmaceutical, Inc. and Lundbeck announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for ABILIFY ASIMTUFII (aripiprazole) extended-release injectable suspension for intramuscular use. This formulation is a once-every-two-months injection indicated for the treatment of schizophrenia in adults and as maintenance monotherapy for bipolar I disorder in adults.
Moreover, the clinical trials of antipsychotic drugs are expected to significantly advance the drug development process. For instance, Karuna Therapeutics is advancing its product pipeline by introducing novel drug candidates such as KarXT (xanomeline-trospium) for the treatment of various psychiatric and neurological conditions. Currently, the candidate is being evaluated in late-stage clinical trials as a potential treatment for schizophrenia and psychosis in Alzheimer's disease. In October 2022, the company also announced the data of its Phase III clinical trials.
Thus, the surging awareness, combined with new launches based on innovative R&D, is expected to drive the market growth for antipsychotic drugs during the forecast period. Therefore, all the factors stated above collectively will drive the overall antipsychotic drugs market throughout the forecast period from 2024 to 2030.
However, the high cost of drug development and launches, addiction caused due to antipsychotic drugs, and the stringent regulatory approval process may halt the market growth of antipsychotic drugs.
Antipsychotic Drugs Market Segment Analysis:
Antipsychotic Drugs Market by Indication (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, and Others), Drug Class (First Generation or Typical Antipsychotics [Haloperidol, Prochlorperazine, and Others], Second Generation or Atypical Antipsychotics [Clozapine, Risperidone, and Others], Third Generation [Abilify and Others], Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the indication segment of the antipsychotic drugs market, the schizophrenia category is expected to have a significant revenue share in the year 2023. This iss primarily owing to the increasing prevalence of schizophrenia across the globe. Also, the expanding launches and strategic investments, and other activities by key players in the segment will support the market growth during the forecast period.
For instance, as per the WHO statistics in 2022, it stated that schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) worldwide and this rate is 1 in 222 people (0.45%) among adults on an average. Its onset is most often during late adolescence and the twenties, and the onset tends to happen earlier among men than among women.
Further, as per a recent study done by the National Alliance on Mental Illness, nearly 1.5 million people yearly suffer from schizophrenia, in the US. The same source stated that at some time during their life, about 1 in 100 people will suffer an episode of schizophrenia.
Moreover, the presence of a robust number of schizophrenia-treating antipsychotic drugs in the pipeline is also expected to drive its market growth. For instance, in February 2022, Alkermes plc received positive results from ENLIGHTEN-Early, a phase 3b study that assessed the effect of LYBALVI (olanzapine and samidorphan) compared to olanzapine on body weight in young adult patients (age 16 to 39; mean age: 26 years) with schizophrenia, schizophreniform disorder or bipolar I disorder.
Various other strategic steps taken by key players in the market will also help in driving the market growth of antipsychotics. For instance, in January 2022, Otsuka America Pharmaceutical, Inc. and H. Lundbeck A/S received the U.S. FDA approval for the supplemental new drug application (sNDA) of REXULTI (brexpiprazole) for the treatment of schizophrenia in pediatric patients from ages 13 to 17.
Therefore, owing to the above-mentioned factors, the demand for schizophrenia-treating antipsychotic drugs will upsurge, due to which this category is expected to witness considerable growth, eventually contributing to the growth of the overall antipsychotic drugs market during the forecast period.
North America is expected to dominate the overall antipsychotic drugs market:
Among all the regions, North America is expected to dominate the antipsychotic drugs market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030.
This can be ascribed to the increasing demand for antipsychotic drugs in the region owing to the increasing prevalence of various mental disorders in the region. Further, the rising burden of geriatric patients, the presence of key domicile players in the region, surging drug approvals and launches, and others are among key factors that contribute to the growth of the antipsychotic drugs market in North America during the forecast period from 2024 to 2030.
As per the latest study conducted by the National Alliance on Mental Illness, 1 in 5 US adults experience mental illness each year and 1 in 20 US adults experience serious mental illness each year. Further, 1 in 6 US youth aged 6-17 experience a mental health disorder each year on average. As per Depression and Bipolar Support Alliance 2022, bipolar disorder affects approximately 5.7 million adult Americans or about 2.6% of the US population aged 18 and older every year.
Thus, the rising prevalence of mental disorders such as bipolar disorder, dementia, depression, and others will propel the demand for antipsychotic drugs during the forecast period. Additionally, the rising burden of geriatric patients prone to mental disorders is also going to propel the demand for antipsychotic drugs in the region.
The market players in the North American region are continuously concentrating on the development of novel drugs to tackle mental disorder indications using antipsychotic drugs, and they are also adopting various strategies to develop better drugs with reduced side effects. For instance, in April 2023, Teva Pharmaceuticals and MedinCell announced that the U.S. Food and Drug Administration (FDA) granted approval for its UZEDY (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. UZEDY is the first subcutaneous, long-acting risperidone formulation, utilizing MedinCell's proprietary SteadyTeq copolymer technology to ensure controlled, steady release of the active compound. This technology allows for therapeutic blood concentrations to be achieved within 6 to 24 hours following a single dose.
Also, in September 2022, Zydus Lifesciences' US subsidiary Zydus Pharmaceuticals (USA) Inc. received final approval from the United States Food and Drug Administration (USFDA) to market Cariprazine Capsules, USP 1.5 mg, 3 mg, 4.5 mg, and 6 mg. Cariprazine is an atypical antipsychotic indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar disorder.
Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North America region in the antipsychotic drugs market during the forecast period from 2024 to 2030.
Antipsychotic Drugs Market key players:
Some of the key market players operating in the Antipsychotic Drugs market Eli Lily and Company, Janssen Global Services, LLC, Pfizer Inc, Otsuka Pharmaceutical Co., Ltd, Alkermes, Inc, Dr. Reddy's Laboratories Ltd, AbbVie Inc, Sun Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC, Alvogen, Hikma Pharmaceuticals PLC, Viatris Inc, Bayer AG, Bristol-Myers Squibb Company, Cardinal Health Inc, Sanis Health Inc, H. Lundbeck A/S, Elikem Pharmaceuticals Pvt Ltd, Devlife Corporation Private Limited, GSK plc, and others.
Recent Developmental Activities in the Antipsychotic Drugs Market:
Key Takeaways from the Antipsychotic Drugs Market Report Study
Target audience who can be benefited from this Antipsychotic Drugs Market Report Study
Frequently Asked Questions for the Antipsychotic Drugs Market:
The antipsychotic drugs are prescribed as short or long-term treatment of mental health problems. These drugs help alleviate and control psychotic symptoms such as anxiety, depression, delusions, hallucinations, or mania.
The antipsychotic drugs market was valued at USD 13,404.76 million in 2023 and is likely to register a CAGR of 6.62% during the forecast period from 2024 to 2030 to reach USD 19,653.29 million by 2030.
The antipsychotic drugs market is experiencing significant growth, driven by the growing prevalence of mental disorders, increasing geriatric population base prone to mental related ailments, increasing focus of governments and health care organizations on mental health, surging new drug launches and approvals, presence of key players in the market, and others which will create an exigency for the antipsychotic drugs. Therefore, the market for antipsychotic drugs is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.
Some of the key market players operating in antipsychotic drugs market include Eli Lily and Company, Janssen Services, LLC, Pfizer Inc, Otsuka Pharmaceutical Co., Ltd, Alkermes, Inc, Dr. Reddy's Laboratories Ltd, AbbVie Inc, Sun Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC, Alvogen, Hikma Pharmaceuticals PLC, Viatris Inc, Bayer AG, Bristol-Myers Squibb Company, Cardinal Health Inc, Sanis Health Inc, H. Lundbeck A/S, Elikem Pharmaceuticals Pvt Ltd, Devlife Corporation Private Limited, GSK plc, and others.
Among all the regions, North America is estimated to hold a significant revenue share in the antipsychotic drugs market. This can be ascribed to the increasing demand for antipsychotic drugs among patients in the region owing to the increasing prevalence of various mental disorders such as depression, bipolar disorders, substance-induced psychoses, schizophrenia, and others. Further, the rising burden of geriatric patients and the presence of key domicile players in the region act as supportive factors for the North America antipsychotic drugs market growth during the forecast period from 2024 to 2030.